Phaseline

Companies › L & L Bio Co., Ltd., Ningbo, China

L & L Bio Co., Ltd., Ningbo, China: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LB1410
anti-PD-1 and anti-TIM-3 bispecific antibody
PDCD1, HAVCR2Phase 1Solid TumorDec 2026
LB4330
anti-claudin18.2/IL-10 fusion protein
CLDN18, IL10Phase 1Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05357651LB1410Phase 1Solid TumorOncologyDec 2026
NCT06468358LB1410Phase 1Solid TumorOncologyDec 2026
NCT06468358LB4330Phase 1Solid TumorOncologyDec 2026

Targets

PDCD1 (1) HAVCR2 (1) CLDN18 (1) IL10 (1)

Companies with the same targets

AstraZeneca Akeso Innovent Biologics (Suzhou) Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Astellas Regeneron Pharmaceuticals Merck & Co. (MSD) Ono Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.